Pharming’s journey has been – and still is – an unequalled rollercoaster ride. While the route forward planned out by CEO Sijmen de Vries initially met with scepticism, the company today is doing better than ever before. For the first time in its long history, Pharming actually is profitable. We are thrilled Sijmen de Vries will join our Biotech Thursday to inspire and educate us with his fascinating story.
Last month, Probiodrug presented encouraging early-stage results of its PQ912 trial. The Amsterdam-listed company boldly works on a therapy for Alzheimer’s Disease, seemingly unconcerned by the dreaded image the devastating disease gained after numerous failed drug trials. CEO Konrad Glund will enlighten us on how a German company ended up at the Amsterdam Stock Exchange, on Probiodrug’s progress to date and, of course, the challenging road that lies ahead.
After the successful acquisition of ProFibrix in 2013 by The Medicines Company, Jaap Koopman founded Fibriant in 2015. The company has a strong R&D focus and aims to create and develop new innovative healthcare solutions all based on the unique properties of human fibrinogen. We are excited that Jaap will share his experience with us.
In conclusion: don’t miss this unique chance to learn from these biotech headliners and the opportunity to ask them all about the secrets of their success.
Venue: Muntgebouw Utrecht
More information: https://www.hollandbio.nl/events/hollandbio-biotech-thursday-september
About Biotech Thursday: HollandBIO’s Biotech Thursdays aim to boost a well-connected biotech network and to share knowlegde. Each Biotech Thursday zooms in on a present-day topic. The recipe is as simple as effective: three speakers presenting their views on a specific topic, ample time for discussion and a reception to talk on with peers.